Skip to search boxSkip to navigationSkip to main content

Viral escape by selection of cytotoxic T cell-resistant variants in influenza a virus pneumonia

*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Antigenic variation is a strategy exploited by influenza viruses to promote survival in the face of the host adaptive immune response and constitutes a major obstacle to efficient vaccine development. Thus, variation in the surface glycoproteins hemagglutinin and neuraminidase is reflected by changes in susceptibility to antibody neutralization. This has led to the current view that antibody-mediated selection of influenza A viruses constitutes the basis for annual influenza epidemics and periodic pandemics. However, infection with this virus: elicits a vigorous protective CD8+ cytotoxic T lymphocyte (CTL) response, suggesting that CD8+ CTLs might exert selection pressure on the virus. Studies with influenza A virus- infected transgenic mice bearing a T cell receptor (TCR) specific for viral nucleoprotein reveal that virus reemergence and persistence occurs weeks after the acute infection has apparently been controlled. The persisting virus is no longer recognized by CTLs, indicating that amino acid changes in the major viral nucleoprotein CTL epitope can be rapidly accumulated in vivo. These mutations lead to a total or partial loss of recognition by polyclonal CTLs by affecting presentation of vital peptide by class I major histocompatibility complex (MHC) molecules, or by interfering with TC recognition of the mutant peptide-MIHC complex. These data illustrate the distinct features of pulmonary immunity in selection of CTL escape variants. The likelihood of emergence and the biological impact of CTL escape variants on the clinical outcome of influenza pneumonia in an immunocompetent host, which is relevant for the design of preventive vaccines against this and other respiratory vital infections, are discussed.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 1853-1867 (15 pages)

Journal (Volume, Issue Number)

Journal of Experimental Medicine (Volume 191, Issue 11)

Publication milestones

  • Published - 06/05/2000

Publication status

Published - 06/05/2000

ISSN

0022-1007

Publication IDs

  • Scopus: 0034608650
  • PubMed: 10839802

Publication metrics

Metrics

SciVal
FWCI
1.05
SciVal
Author count
5
SciVal
citations
78
SciVal
Paper percentile
90
SciVal
Top percentile
10
Fractional count
2
Fractional count
0.40
Fractional count
3
Fractional count
0.60
Fractional count
2
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Citation count
87
Captures
51